Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Ipsen Positive On Palovarotene Despite Troubled Past

Filings For FOP In Early 2021

11 Dec 2020

• By Kevin Grogan

folders — Filings nearly ready for Ipsen's ultra rare bone disease drug • Source: Shutterstock

Related Content

Ipsen CEO Outlines Strategy For Long-Term Success

04 Dec 2020

New Analyses Allow Restart Of Ipsen's Palovarotene Clinical Program

26 Mar 2020

Ipsen Commercial Chief: Buying Clementia Will Bolster Rare Disease Franchise

25 Feb 2019

Ipsen’s Palovarotene Hit By FDA Clinical Hold

09 Dec 2019

Related Companies

Ipsen SA

Clementia Pharmaceuticals, Inc.

Regeneron Pharmaceuticals, Inc.

Additional Topics

Rare Diseases Drug Review Strategy Leadership Pediatrics BioPharmaceutical

More from Rare Diseases

More from Scrip

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.